Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300353 | 0.78 | — | — | |
| Fluoride SCHEMBL27598849 | 0.76 | CA2 (0.30) | CA2 | |
| SCHEMBL27723205 | 0.75 | — | — | |
| SCHEMBL10794666 | 0.75 | TSHR (0.32) | TSHR | |
| SCHEMBL18692048 | 0.75 | FNTA (0.41) | ALDH1A1TSHR | |
| Methacrylic Acid SCHEMBL1133554 | 0.71 | CA1 (0.36) | CA2ALDH1A1TSHR | |
| SCHEMBL7605882 | 0.70 | — | — | |
| SCHEMBL92311 | 0.70 | — | — | |
| Glycinebetaine SCHEMBL21522630 | 0.70 | MEN1 (0.30) | — | |
| SCHEMBL28696663 | 0.70 | FNTA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3777836-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN, INC. (US) | 2021-02-17 | — | — | EP | claimed |
| EP-2952178-B1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | claimed |
| EP-2952178-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN, INC. (US) | 2015-12-09 | — | — | EP | claimed |
| EP-1811959-B1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-5130389-A | Sulfonate anion monomer, a comonomer and a crosslinking agent for improving absorbancy of paper towels or disposable diapers | PHILLIPS PETROLEUM COMPANY (US) | 1992-07-14 | — | — | US | claimed |
| US-5075399-A | Highly absorbent to aqueous electrolyte solutions | PHILLIPS PETROLEUM COMPANY (US) | 1991-12-24 | — | — | US | claimed |
| US-11903986-B2 | Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye | AKRIVISTA LLC (US) | 2024-02-20 | — | — | US | disclosed |
| EP-1811959-B2 | OPHTHALMIC COMPOSITIONS | ALLERGAN INC (US) | 2022-06-15 | — | — | EP | disclosed |
| US-20210251961-A1 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME | ALLERGAN INC (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3777836-A1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN, INC. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-2952178-B1 | OPHTHALMIC COMPOSITIONS AND METHODS FOR TREATING EYES | ALLERGAN INC (US) | 2020-09-02 | — | — | EP | disclosed |
| US-20200069576-A1 | COMPOSITIONS CONTAINING ALPHA-2-ADRENERGIC AGONIST COMPONENTS | ALLERGAN INC (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3500344-A1 | METHODS OF DIAGNOSING AND TREATING DRY EYE SYNDROME AND COMPOSITIONS FOR TREATING A HUMAN EYE | Akrivista, LLC (US) | 2019-06-26 | — | — | EP | disclosed |
| WO-1998030248-A2 | COMPOSITIONS AND METHODS FOR STORING CONTACT LENSES | ALLERGAN SALES, INC. (US) | 1998-07-16 | — | — | WO | disclosed |
| EP-0835142-A1 | COMPOSITIONS AND METHODS FOR DISINFECTING A CONTACT LENS AND DETECTING THE PRESENCE OF AN OXIDATIVE DISINFECTANT | Allergan (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998005365-A2 | COMPOSITIONS AND METHODS FOR DISINFECTING CONTACT LENSES AND PRESERVING CONTACT LENS CARE PRODUCTS | ALLERGAN SALES, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| US-5703024-A | AQUEOUS SOLUTION CONTAINING HYDROGEN PEROXIDE, REDOX ACTIVE TRANSITION METAL COMPOUND AS COLOR INDICATOR, POLYANIONIC COMPONENT TO PREVENT STAINING OF LENS IMMERSED IN SOLUTION | ALLERGAN (US) | 1997-12-30 | — | — | US | disclosed |
| US-5648074-A | POLYANIONIC COMPOUND, CHLORINE DIOXIDE | ALLERGAN (US) | 1997-07-15 | — | — | US | disclosed |
| WO-1997002053-A1 | COMPOSITIONS AND METHODS FOR DISINFECTING A CONTACT LENS AND DETECTING THE PRESENCE OF AN OXIDATIVE DISINFECTANT | ALLERGAN (US) | 1997-01-23 | — | — | WO | disclosed |
| US-5075399-A | Highly absorbent to aqueous electrolyte solutions | PHILLIPS PETROLEUM COMPANY (US) | 1991-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251961-A1 | COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAME | MUC1, EPCAM, MYOC | CA2 1279/4885ALDH1A1 2009/4885TDP1 4237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.